Format

Send to

Choose Destination
Alzheimers Dement. 2015 Aug;11(8):975-85. doi: 10.1016/j.jalz.2015.05.018. Epub 2015 Jun 30.

[(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-β pathology.

Author information

1
Institute of Pathology-Laboratory of Neuropathology, Center for biomedical Research, University of Ulm, Ulm, Germany. Electronic address: dietmar.thal@uni-ulm.de.
2
Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, AZ, USA.
3
Life Sciences R&D Biometrics, GE Healthcare, Princeton, NJ, USA.
4
Life Sciences R&D, GE Healthcare, Uppsala, Sweden; Department of Surgical Sciences: Radiology, Uppsala University, Uppsala, Sweden.
5
Pathology and Tumour Biology, Leeds Institute of Molecular Medicine, St. James Hospital, Leeds, UK.
6
Life Sciences R&D, GE Healthcare, Amersham, UK.

Abstract

BACKGROUND:

Amyloid positron emission tomography (PET) has become an important tool to identify amyloid-β (Aβ) pathology in Alzheimer's disease (AD) patients. Here, we determined the diagnostic value of the amyloid PET tracer [(18)F]flutemetamol in relation to Aβ pathology at autopsy.

METHODS:

[(18)F]flutemetamol PET was carried out in a cohort of 68 patients included in a [(18)F]flutemetamol amyloid PET imaging end-of-life study (GE067-007). At autopsy, AD pathology was determined and Aβ plaque pathology was classified into phases of its regional distribution (0-5).

RESULTS:

[(18)F]flutemetamol PET was universally positive in cases with advanced stage postmortem Aβ pathology (Aβ phases 4 and 5). Negative amyloid PET was universally observed in nondemented or non-AD dementia cases with initial Aβ phases 1 and 2, whereas 33.3% of the phase 3 cases were positive.

CONCLUSIONS:

[(18)F]flutemetamol amyloid PET detects primarily advanced stages of Aβ pathology in preclinical and symptomatic AD cases.

KEYWORDS:

Alzheimer's disease; Amyloid; Amyloid PET; Preclinical stage; [(18)F]flutemetamol

PMID:
26141264
DOI:
10.1016/j.jalz.2015.05.018
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center